Novocure Ltd. (NVCR) News
Filter NVCR News Items
NVCR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NVCR News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest NVCR News From Around the Web
Below are the latest news stories about NOVOCURE LTD that investors may wish to consider to help them evaluate NVCR as an investment opportunity.
Novocure anticipates higher-than-expected 2024 revenuesMore on NovoCure |
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare ConferenceBAAR, Switzerland, January 03, 2025--Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference |
Novocure price target raised to $42 from $28 at Piper SandlerPiper Sandler raised the firm’s price target on Novocure (NVCR) to $42 from $28 and keeps an Overweight rating on the shares. The firm thinks the catalyst path for Novocure shares screens more favorably for medical technology investors that can better handicap upcoming “medtech-like” milestones for the company, including new indication commercialization, regulatory submission and approvals, and securing payer coverage. Piper introduced estimates through 2028 and highlights the company’s improved |
Why NovoCure Stock Was Winning Big This WeekCancer-targeting biotech NovoCure (NASDAQ: NVCR) had some highly positive news from the laboratory to deliver earlier this week, and investors couldn't grab hold of the stock fast enough. This momentum was helped by price target increases from analysts. According to data compiled by S&P Global Market Intelligence, those bullish market players propelled the stock nearly 33% higher week to date as of early Friday morning. |
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?The life science industry recently gave folks diagnosed with pancreatic cancer the best news this group has received in a very long time. Novocure (NASDAQ: NVCR) and its international partner Zai Lab (NASDAQ: ZLAB) announced successful top-line results from the Panova-3 study on Dec. 2, 2024. In a nutshell, it showed that the company's electric field-generating devices can improve pancreatic cancer patients' odds of survival. |
Novocure Stock Earns 96 RS RatingOn Tuesday, Novocure[ticker symb=NVCR] stock got a positive adjustment to its Relative Strength (RS) Rating, from 73 to 96. The oncology company had some good news Monday announcing success in its pancreatic cancer study. |
NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study GoalsNovocure stock soars 49% as the late-stage study of TTFields therapy for treating pancreatic adenocarcinoma meets the primary endpoint of overall survival. |
Zai Lab, Novocure announce PANOVA-3 trial met primary endpointZai Lab (ZLAB) and Novocure (NVCR) announced that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival, or mOS, versus control. PANOVA-3 evaluated the use of Tumor Treating Fields, or TTFields, therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma. In the intent-to-treat population, patients treated with TTFields ther |
Novocure Launches 49% After Pancreatic Cancer Treatment SucceedsNovocure stock catapulted early Monday after the company's cancer-treating device succeeded in a study of patients with pancreatic cancer. |
Novocure seeks approval after pancreatic cancer wearable scores at Phase IIINovocure’s TTFields therapy combined with chemo improved overall survival by 16.2 months compared to 14.16 months with chemo alone. |